These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 2097305)

  • 1. International nifedipine trial on anti-atherosclerotic therapy (INTACT)--methodologic implications and results of a coronary angiographic follow-up study using computer-assisted film analysis.
    Jost S; Deckers J; Rafflenbeul W; Hecker H; Reiber JH; Nikutta P; Wiese B; Hugenholtz P; Lichtlen P
    Int J Card Imaging; 1990-1991; 6(2):117-33. PubMed ID: 2097305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Computer-assisted geometric measuring technic in coronary angiography interval studies: results of initial angiograms of the International Nifedipine Trial of Anti-atherosclerotic Therapy (INTACT) study].
    Jost S; Deckers J; Nellessen U; Rafflenbeul W; Hecker H; Reiber JH; Lippolt P; Hugenholtz PG; Lichtlen PR
    Z Kardiol; 1989 Jan; 78(1):23-32. PubMed ID: 2646838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Features of the angiographic evaluation of the INTACT study. International Nifedipine Trial on Antiatherosclerotic Therapy.
    Jost S; Deckers J; Rafflenbeul W; Hecker H; Nellessen U; Wiese B; Hugenholtz PG; Lichtlen PR
    Cardiovasc Drugs Ther; 1990 Aug; 4 Suppl 5():1037-45. PubMed ID: 2076391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of coronary stenoses is related to baseline severity--a prospective quantitative angiographic analysis in patients with moderate coronary disease. INTACT Investigators. International Nifedipine Trial on Antiatherosclerotic Therapy.
    Jost S; Deckers JW; Nikutta P; Wiese B; Rafflenbeul W; Hecker H; Lippolt P; Lichtlen PR
    Eur Heart J; 1994 May; 15(5):648-53. PubMed ID: 8056005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical application of quantitative coronary angiography using the CAAS system: preliminary results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).
    Jost S; Deckers JW; Nellessen U; Rafflenbeul W; Hecker H; Reiber JH; Hugenholtz PG; Lichtlen PR
    Int J Card Imaging; 1988; 3(2-3):75-86. PubMed ID: 3049846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators.
    Jost S; Rafflenbeul W; Deckers J; Wiese B; Hecker H; Nikutta P; Lippolt P; Lichtlen P
    Eur J Epidemiol; 1992 May; 8 Suppl 1():107-19. PubMed ID: 1505647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).
    Lichtlen PR; Hugenholtz PG; Rafflenbeul W; Hecker H; Jost S; Nikutta P; Deckers JW
    Cardiovasc Drugs Ther; 1990 Aug; 4 Suppl 5():1047-68. PubMed ID: 2076392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative angiographic follow-up studies on the development of coronary artery disease: which coronary segments should be analyzed? Experience from INTACT.
    Jost S; Deckers J; Rafflenbeul W; Reiber JH; Nikutta P; Wiese B; Hecker H; Lippolt P; Riedel M; Nolte CW
    Int J Card Imaging; 1993 Mar; 9(1):29-37. PubMed ID: 8491998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the selection of angiographic projections on the results of coronary angiographic follow-up trials. International Nifedipine Trial on Antiatherosclerotic Therapy Investigators.
    Jost S; Deckers J; Nikutta P; Reiber JH; Rafflenbeul W; Wiese B; Hecker H; Lichtlen P
    Am Heart J; 1995 Sep; 130(3 Pt 1):433-9. PubMed ID: 7661057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anatomical progression of coronary artery disease in humans as seen by prospective, repeated, quantitated coronary angiography. Relation to clinical events and risk factors. The INTACT Study Group.
    Lichtlen PR; Nikutta P; Jost S; Deckers J; Wiese B; Rafflenbeul W
    Circulation; 1992 Sep; 86(3):828-38. PubMed ID: 1516195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of coronary artery disease is dependent on anatomic location and diameter. The INTACT investigators.
    Jost S; Deckers JW; Nikutta P; Rafflenbeul W; Wiese B; Hecker H; Lippolt P; Lichtlen PR
    J Am Coll Cardiol; 1993 May; 21(6):1339-46. PubMed ID: 8473639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International nifedipine trial on antiatherosclerotic therapy (INTACT).
    Lichtlen PR; Nellessen U; Rafflenbeul W; Jost S; Hecker H
    Cardiovasc Drugs Ther; 1987; 1(1):71-9. PubMed ID: 3154311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators.
    Lichtlen PR; Hugenholtz PG; Rafflenbeul W; Hecker H; Jost S; Deckers JW
    Lancet; 1990 May; 335(8698):1109-13. PubMed ID: 1971861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis.
    Waters D; Lespérance J; Francetich M; Causey D; Théroux P; Chiang YK; Hudon G; Lemarbre L; Reitman M; Joyal M
    Circulation; 1990 Dec; 82(6):1940-53. PubMed ID: 2242520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy.
    Hahmann HW; Bunte T; Hellwig N; Hau U; Becker D; Dyckmans J; Keller HE; Schieffer HJ
    Am J Cardiol; 1991 May; 67(11):957-61. PubMed ID: 2018014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term luminal renarrowing after successful elective coronary angioplasty of total occlusions. A quantitative angiographic analysis.
    Violaris AG; Melkert R; Serruys PW
    Circulation; 1995 Apr; 91(8):2140-50. PubMed ID: 7697842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study).
    Shinoda E; Yui Y; Kodama K; Hirayama A; Nonogi H; Haze K; Sumiyoshi T; Hosoda S; Kawai C;
    Hypertension; 2005 Jun; 45(6):1153-8. PubMed ID: 15851624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of quantitative computerized and human panel coronary endpoint measures: implications for the design of angiographic trials.
    Mack WJ; Azen SP; Dunn M; Hodis HN
    Control Clin Trials; 1997 Apr; 18(2):168-79. PubMed ID: 9129860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function).
    ENCORE Investigators
    Circulation; 2003 Jan; 107(3):422-8. PubMed ID: 12551866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
    Cashin-Hemphill L; Kramsch DM; Azen SP; DeMets D; DeBoer LW; Hwang I; Vailas L; Hirsch LJ; Mack WJ; DeBoer L
    Online J Curr Clin Trials; 1992 Oct; Doc No 26():[9897 words; 83 paragraphs]. PubMed ID: 1343613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.